Comparison of the Clinical Outcomes between Anti-thymocyte Globulin and Basiliximab Induction Therapy in Deceased Donor Kidney Transplantation: Single Center Experience.
10.4285/jkstn.2015.29.2.61
- Author:
Seong Uk CHEON
1
;
Ju Ik MOON
;
In Seok CHOI
;
Se Hee YOON
;
Won Min HWANG
;
Sung Ro YUN
Author Information
1. Department of Surgery, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea. monjuik@naver.com
- Publication Type:Original Article
- Keywords:
Antithymocyte globulin;
Basiliximab;
Kidney transplantation
- MeSH:
Antilymphocyte Serum*;
Appointments and Schedules;
Creatinine;
Follow-Up Studies;
Glomerular Filtration Rate;
Graft Survival;
Hepacivirus;
Hepatitis B virus;
Humans;
Incidence;
Kidney Transplantation*;
Tissue Donors*
- From:The Journal of the Korean Society for Transplantation
2015;29(2):61-67
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The aim of this study is to evaluate the clinical outcomes between anti-thymocyte globulin (ATG) and basiliximab induction in deceased donor kidney transplantation (DDKT). METHODS: Between May 2006 and February 2015, 40 patients underwent DDKT at our institution. Three cases (7.5%) of them were lost during the following-up schedule. In this study, ATG induction criteria were donor age >50 years old or donor creatinine level >1.3 mg/dL except hepatitis B virus positive and hepatitis C virus positive recipients. Recipients were divided into two groups: the ATG group (n=20) and the basiliximab group (n=17). RESULTS: The 1-year patient survival in the ATG group was 89.4% compared to 93.8% in the basiliximab group (P=0.989). Graft survival for a 1 year in the ATG and the basiliximab group was 89.1% and 93.8%, respectively (P=0.967). Incidences of acute rejection episodes were more prevalent in the basiliximab group (15.0% vs. 29.4%, P=0.428). The glomerular filtration rate level by period of recipients was not different in both group (12th month, 64.60+/-16.17 mg/dL vs. 68.51+/-18.60 mg/dL, P=0.544). The overall complications during the follow-up were not significantly different in both groups (90.0% vs. 76.5%, P=0.383). CONCLUSIONS: The results showed that there was no difference in the patient survival and graft survival between induction of ATG and basiliximab of the DDKT were not different. Therefore, use of both induction agents led to a good patient and graft survival and ATG might be a safe and preferable agent for relatively poor renal function of donor in kidney transplantation.
